Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study

scientific article

Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.OPHTHA.2014.08.024
P698PubMed publication ID25312044
P5875ResearchGate publication ID266749528

P50authorClaire Melissa VajdicQ40510446
Peter McCluskeyQ62495591
William B YatesQ87822150
P2093author name stringDenis Wakefield
Renhua Na
P433issue2
P921main subjecteye diseaseQ3041498
P304page(s)265-273
P577publication date2014-10-11
P1433published inOphthalmologyQ7098109
P1476titleMalignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study
P478volume122

Reverse relations

cites work (P2860)
Q38849274HLA-B27 Anterior Uveitis: Immunology and Immunopathology
Q47932596Immunosuppression for the Uveitides
Q36090279Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Tr
Q38938749Sirolimus for the treatment of noninfectious uveitis
Q38806044Unmet Needs and Future Directions in Inflammatory Eye Disease
Q49845401[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Search more.